10-Q: Bio-Path Holdings Reports Q1 2025 Results, Cites Ongoing Losses and Need for Additional Capital

Sentiment:

Quarterly Report 15 May 2025 4:18 PM

Bio-Path Holdings reports a net loss of $2.9 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Capital raiseThe company states that it will continue to require substantial additional capital to fund its projected operating requirements.The company may seek to access the public or private equity markets whenever conditions are favorable.The company may seek collaborations and license arrangements for its drug candidates.

Worse than expectedThe company's net loss and low cash balance indicate a worsening financial situation compared to previous periods.The statement about substantial doubt regarding the company's ability to continue as a going concern is a significant negative indicator.

Summary

Bio-Path Holdings reported a net loss of $2.9 million for the first quarter ended March 31, 2025, compared to a net loss of $3.2 million for the same period in 2024.
The company's research and development expenses decreased to $2.0 million from $2.3 million year-over-year, primarily due to timing of patient enrollment in clinical trials.
General and administrative expenses also decreased slightly to $1.3 million from $1.4 million.
As of March 31, 2025, Bio-Path had a cash balance of $0.1 million and an accumulated deficit of $120.4 million.
The company states that its available cash, along with proceeds from a subsequent promissory note, will not be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
Bio-Path is pursuing several drug candidates, including prexigebersen (BP1001), Liposomal Bcl-2 (BP1002), Liposomal STAT3 (BP1003), and BP1001-A, for various cancer indications and obesity.
The company is seeking additional capital through various means, including equity offerings, debt financings, and potential collaborations.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are some positive preclinical and clinical data updates, the overriding concern is the company's precarious financial situation and the explicit statement about its ability to continue as a going concern. This significantly weighs down the overall sentiment.

Positives

Phase 2 clinical trial data for prexigebersen in combination with decitabine and venetoclax shows promising results in AML patients.
Preclinical data suggests BP1001-A could potentially lower blood glucose levels and restore insulin sensitivity, making it a potential candidate for treating obesity in Type 2 diabetes patients.
The company has successfully completed several IND enabling studies for BP1003.
The company is actively pursuing collaborations and license arrangements for its drug candidates.

Negatives

The company has a significant accumulated deficit of $120.4 million.
The company's cash balance is very low at $0.1 million as of March 31, 2025.
The company expresses substantial doubt about its ability to continue as a going concern.
The company has not generated significant revenues to date.
The company is dependent on raising additional capital to fund its operations.

Risks

The company's lack of significant revenue to date and history of recurring operating losses.
The need for substantial additional capital and the risk of being unable to raise it.
The highly competitive nature of the pharmaceutical and biotechnology industry.
The uncertainty of clinical trial outcomes and regulatory approvals.
The risk of delays or termination of clinical trials.
The reliance on third parties for manufacturing and conducting clinical trials.
The volatility of the trading price of the company's common stock.
The company's common stock being thinly traded.
The potential for default under the terms of the March 2025 Promissory Notes and April 2025 Promissory Note.

Future Outlook

The company expects to continue to incur significant operating losses and will require substantial additional capital to fund its projected operating requirements. The company may seek to access the public or private equity markets whenever conditions are favorable and may seek collaborations and license arrangements for its drug candidates.

Management Comments

Management believes that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients.
Management believes that BP1002 may be a potential treatment for venetoclax-relapsed AML patients.
Management intends to file an IND with the FDA in 2025 to initiate a first-in-human Phase 1 clinical trial for BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, focusing on RNAi nanoparticle drug development for oncology and obesity. The changing landscape of AML treatment, with the approval of venetoclax in combination with LDAC, decitabine, or azacytidine, has influenced the company's clinical trial strategies. The company is also exploring the development of BP1001-A as a drug candidate to target insulin resistance, a major contributor to obesity, Type 2 diabetes and other related metabolic diseases.

Comparison to Industry Standards

It is difficult to compare Bio-Path Holdings directly to industry standards due to its unique DNAbilize platform and specific drug candidates.
However, the company's approach of targeting specific proteins with RNAi nanoparticle technology aligns with broader industry trends in precision medicine.
The company's focus on AML and pancreatic cancer addresses significant unmet needs in oncology, similar to other companies developing novel therapies for these diseases.
The company's exploration of BP1001-A for obesity reflects the growing interest in developing new treatments for metabolic diseases, with companies like Novo Nordisk and Eli Lilly leading the way with GLP-1 receptor agonists.
The company's financial situation, with significant accumulated deficit and reliance on external funding, is not uncommon for early-stage biotechnology companies, but it highlights the importance of achieving clinical milestones and securing partnerships to ensure long-term sustainability.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and potential need for further dilution.
Employees face uncertainty due to the company's going concern issues and potential for workforce reductions.
Patients may benefit from the company's drug development programs, but the company's financial situation raises concerns about the long-term viability of these programs.
Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

Continue enrollment in Phase 2 clinical trial for prexigebersen in AML.
Commence Phase 1b portion of the BP1002 clinical trial in combination with decitabine in refractory/relapsed AML patients.
Complete the additional IND enabling study for BP1003 and file an IND application.
Complete enrollment for the second dose cohort of BP1001-A Phase 1/1b clinical trial.
Continue animal studies to evaluate the efficacy of BP1001-A as a potential treatment for obesity and related metabolic diseases.
File an IND with the FDA in 2025 to initiate a first-in-human Phase 1 clinical trial for BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients.
Pursue FDA expedited programs for Fast Track designation for prexigebersen.
Evaluate whether to seek to expand Stage 2 of the Phase 2 clinical trial in Europe.

Key Dates

Date	Description
April 12, 2016	Date of the Original Commercial Lease between HJF Properties, LLC and Bio-Path Holdings, Inc.
December 12, 2018	Date of the First Amendment to Commercial Lease and Exercise of Option.
October 2020	FDA granted approval of venetoclax in combination with LDAC, decitabine or azacytidine as frontline therapy for newly diagnosed AML.
December 15, 2022	Stockholders approved the Bio-Path Holdings, Inc. 2022 Stock Incentive Plan.
February 22, 2024	Bio-Path Holdings effected a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.
March 25, 2024	The company entered into a securities purchase agreement with a certain institutional and accredited investor pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 75,000 shares of its common stock for gross proceeds of approximately $0.3 million.
April 4, 2024	The company entered into the At The Market Offering Agreement with Wainwright, as sales agent, pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of its common stock.
April 18, 2024	The company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the Company agreed to sell, in a registered direct offering, an aggregate of 375,000 shares of its common stock for gross proceeds of approximately $1.2 million.
June 3, 2024	The company entered into a securities purchase agreement with a certain institutional and accredited investor pursuant to which the Company agreed to sell, in a private placement, an aggregate of (i) 180,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 1,629,955 shares of its common stock at an exercise price of $0.001 per share, (iii) series A warrants to purchase up to 1,809,955 shares of its common stock at an exercise price of $2.00 per share and (iv) series B warrants to purchase up to 1,809,955 shares of its common stock at an exercise price of $2.00 per share for gross proceeds of approximately $4.0 million.
October 8, 2024	The company entered into a securities purchase agreement with a certain institutional and accredited investor pursuant to which the Company agreed to sell, in a private placement, an aggregate of (i) pre-funded warrants to purchase up to 4,597,702 shares of its common stock at an exercise price of $0.001 per share, (ii) series A warrants to purchase up to 6,407,657 shares of its common stock at an exercise price of $1.00 per share and (iii) series B warrants to purchase up to 6,407,657 shares of its common stock at an exercise price of $1.00 per share for gross proceeds of approximately $4.0 million.
December 11, 2024	The company announced that the Phase 1 clinical trial for BP1002 was discontinuing enrollment.
December 19, 2024	The company announced the results of its initial preclinical work; BP1001-A, by downregulating Grb2 expression, increased the levels of phosphorylated AKT and phosphorylated FOXO-1 (a downstream AKT effector) in myoblast and hepatoma cells in the presence of insulin.
February 14, 2025	The Nasdaq Stock Market LLC (Nasdaq) notified the Company that the Nasdaq Hearings Panel (the Panel) determined to delist the Companys Common Stock, par value $0.001 per share.
February 19, 2025	Trading of our Common Stock was suspended on The Nasdaq Capital Market and trading of our Common Stock commenced on the OTCQB Venture Market under the ticker symbol BPTH.
March 6, 2025	The company entered into a securities purchase agreement with 1800 Diagonal Lending LLC, a Virginia limited liability company (the Lender), an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $161,000 (the First Promissory Note) for a purchase price of $140,000 after deducting the original issue discount of $21,000.
March 18, 2025	The company announced preclinical results that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models.
March 28, 2025	The company entered into a securities purchase agreement with the Lender, an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $100,050 (the Second Promissory Note and together, with the First Promissory Note, the March 2025 Promissory Notes) for a purchase price of $87,000 after deducting the original issue discount of $13,050.
March 31, 2025	End of the reporting period for the Q1 2025 results.
April 10, 2025	Date of the Second Amendment to Lease Agreement, by and between the Company and HJF Properties, LLC.
April 28, 2025	The company entered into a securities purchase agreement with Quick Capital, LLC, a Wyoming limited liability company, an accredited investor, for the issuance and sale of a promissory note in the aggregate principal amount of $161,000 (the April 2025 Promissory Note) for a purchase price of $140,000 after deducting the original issue discount of $21,000.
May 1, 2025	Renewal Effective Date of the lease for the laboratory space located in Bellaire, Texas.
May 9, 2025	The Company had 8,307,892 outstanding shares of common stock, par value $0.001 per share.
April 30, 2026	Expiration Date of the lease for the laboratory space located in Bellaire, Texas.

Keywords

Bio-Path Holdings, RNAi nanoparticle, Oncology, Obesity, Prexigebersen, BP1001, BP1002, BP1003, BP1001-A, Clinical trials, AML, STAT3, Grb2, Financial results, Going concern, Capital raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.